Vertex Pharmaceuticals Incorporated VRTX
Set alert
553.15 USD -5.73 -1.03%
At close
568.00 +14.85 +2.68%
Pre-market · Nov 3, 8:44 AM ET
544.09 Day range 568.67
403.16 52-week range 568.67
- YTD
- +22.01%
- 1 year
- +29.85%
- Open
- 560.88
- Prev close
- 558.88
- Mkt cap
- 140.11B
- Vol
- 3.21M
- Avg vol
- 1.22M
- EPS
- 17.17
- P/E
- 32.22
- Div yield
- 0.00%
More statistics
- Low
- 544.09
- High
- 568.67
- Forward P/E
- 27.09
- Beta
- 0.28
- Short ratio
- 3.66
- Inst. own
- 98.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2027
- 50-d avg
- 523.21
- 200-d avg
- 479.21
- 1y target
- 571.46
30m chart
Built from the cached five-day intraday bars.
Events in this range
- Nov 2, 2026Earnings: 4.76; estimate 4.82; surprise -1.24%
Signals (19)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 4:00 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 3:55 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 2:25 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 1:55 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 1:25 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 12:55 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 22 hours ago |
| RSI: Overbought | Nov 2, 9:55 AM | 22 hours ago |
| SMA: Bearish | Oct 30, 3:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 9:55 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 4 days ago |
| RSI: Overbought | Oct 29, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 5 days ago |
| RSI: Overbought | Oct 28, 1:25 PM | 5 days ago |
Financial health
Altman Z-Score
9.14 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 4
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 2
- P/B 1
Valuation
P/E 29.3×
FY 2016 5y median 24.2× FY 2025
P/S 9.6×
FY 2016 5y median 9.4× FY 2025
P/B 6.2×
FY 2016 5y median 6.0× FY 2025
P/FCF 36.3×
FY 2016 5y median 23.5× FY 2025
EV/EBITDA 23.6×
FY 2016 5y median 20.7× FY 2025
EV/Sales 9.5×
FY 2016 5y median 9.2× FY 2025
FCF Yield 2.8%
FY 2016 5y median 3.1% FY 2025
Profitability
Gross Margin 85.0%
FY 2016 5y median 87.2% FY 2025
Operating Margin 39.4%
FY 2016 5y median 38.8% FY 2025
Net Margin 32.7%
FY 2016 5y median 32.7% FY 2025
ROE 21.2%
FY 2016 5y median 21.2% FY 2025
ROIC 18.1%
FY 2016 5y median 18.1% FY 2025
ROA 15.1%
FY 2016 5y median 15.9% FY 2025
Growth (YoY)
Revenue 9.6%
FY 2016 FY 2025
Operating Income 2144.1%
FY 2016 FY 2025
EPS (diluted) 836.5%
FY 2016 FY 2025
Free Cash Flow 504.1%
FY 2016 FY 2025
Financial Health
Current Ratio 2.9×
FY 2016 5y median 4.0× FY 2025
Quick Ratio 2.5×
FY 2016 5y median 3.8× FY 2025
Debt / Equity 0.2×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA -0.2×
FY 2016 5y median -2.1× FY 2025
Interest Coverage 358×
FY 2016 5y median 78.6× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
